How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Document Type
Journal Article
Publication Date
12-4-2017
Journal
Diabetes Care
Volume
42
Issue
2
Inclusive Pages
356-363
DOI
10.2337/dc17-1096
APA Citation
Inzucchi, S., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O., George, J., Hantel, S., Bluhmki, E., & Lachin, J. (2017). How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.. Diabetes Care, 42 (2). http://dx.doi.org/10.2337/dc17-1096
Peer Reviewed
1
